Filing Flows › Autolus Therapeutics (AUTL) › Q1 2025
Autolus Therapeutics (AUTL) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Autolus Therapeutics (AUTL) reported revenue of $9.0M for the first quarter 2025 (Q1 2025), -11% from a year earlier and up 310-fold from the quarter before. Operating margin was -726.3%, net loss $70.2M (781.1% of revenue).
Autolus Therapeutics, Q1 2025: revenue $9.0M (-11% year over year), operating margin -726.3%, net loss $70.2M, operating cash flow −$75.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.0M | 310× | -11% |
| Operating profit | −$65.2M | — | — |
| Net earnings | −$70.2M | — | — |
| Operating cash flow | −$75.6M | — | — |
What changed
Revenue was $9.0M in Q1 2025, down 11% year over year and up 30872% from the previous quarter.
Operating costs exceeded revenue by $65.2M, an operating margin of -726.3%. Total costs grew 52% against a revenue fall of 11%. The fastest-growing cost line was SG&A (+62%). The quarter ended with a net loss of $70.2M, wider than the previous quarter's $27.6M loss.
Operating cash flow was −$75.6M. Non-cash charges added back $2.0M of depreciation and amortization and $2.9M of share-based compensation. Working capital and other items used $10.3M. Capital expenditures of $8.2M exceeded it, leaving free cash flow of −$83.8M.
Questions
What was Autolus Therapeutics' revenue in the first quarter 2025?
Autolus Therapeutics (AUTL) reported revenue of $9.0M for the first quarter 2025 (Q1 2025), -11% from a year earlier and up 310-fold from the quarter before.
Was Autolus Therapeutics profitable in the first quarter 2025?
Operating loss was $65.2M (-726.3% of revenue) and net loss $70.2M.